Schizophrenia is not an affective disorder. It is classified as a psychotic disorder, placed in a separate diagnostic category from mood conditions like major depression and bipolar disorder. The two types of illness were formally split more than 120 years ago, and that separation remains the foundation of psychiatric diagnosis today, even as research reveals significant biological overlap between them.
How Schizophrenia Is Classified
In the DSM-5, schizophrenia falls under “Schizophrenia Spectrum and Other Psychotic Disorders.” The ICD-11, the international classification system, uses nearly identical language: “Schizophrenia spectrum and other primary psychotic disorders.” The word “primary” is deliberate. It signals that psychosis is the core feature, not a symptom riding on top of a mood episode.
Affective (mood) disorders occupy their own separate section. This category includes major depressive disorder, bipolar I and II, and cyclothymia. When psychotic symptoms like hallucinations or delusions appear during a mood episode, the diagnosis stays within the mood disorder category, labeled with a “with psychotic features” specifier. The psychosis in that case is considered secondary to the mood disturbance, not a primary condition.
Why the Two Categories Were Separated
The split dates to 1899, when German psychiatrist Emil Kraepelin divided serious mental illness into two groups based on how each one progressed over time. The first, which he called “dementia praecox” (later renamed schizophrenia by Eugen Bleuler), followed a chronic course with progressive cognitive decline. The second, “manic-depressive insanity” (now closest to bipolar disorder), ran in episodes with relatively preserved thinking ability between them.
This distinction, known as the Kraepelinian dichotomy, shaped psychiatry for the entire twentieth century. As of recent reviews, it remains partly valid. The course and cognitive patterns Kraepelin described still hold up in broad strokes, but research over the past few decades has filled in a large gray area between the two poles.
Where Schizophrenia and Mood Disorders Overlap
Despite the clean diagnostic boundary, the biology tells a messier story. A large genetic study examining DNA data from more than one million people with psychiatric diagnoses found that 70 percent of the genetic signal associated with schizophrenia is also associated with bipolar disorder. The two conditions share more genetic architecture with each other than either shares with most other psychiatric illnesses.
Symptom overlap is real, too. People with schizophrenia commonly experience depressive symptoms, and distinguishing those from the “negative symptoms” of schizophrenia (flat emotional expression, loss of motivation, reduced speech) is a genuine clinical challenge. Research suggests that low mood, suicidal thoughts, and pessimism point more specifically toward depression, while reduced speech and blunted facial expression point more toward negative symptoms. But anhedonia (inability to feel pleasure), low energy, and lack of motivation show up in both conditions and can be difficult to untangle.
Even the early warning signs can look similar. In adolescents, the prodromal phase of schizophrenia and the prodromal phase of bipolar disorder share many features. Brief, limited psychotic experiences are more predictive of schizophrenia, while multiple subsyndromal manic symptoms and co-occurring ADHD lean toward an emerging mood disorder. But attenuated psychotic symptoms and negative symptoms alone aren’t specific enough to reliably tell the two apart early on.
Schizoaffective Disorder: The In-Between Diagnosis
Schizoaffective disorder exists precisely because some people don’t fit neatly into either category. It requires both: full mood episodes (depressive or manic) present for the majority of the illness, and at least a two-week stretch of psychotic symptoms without any prominent mood disturbance. If psychosis only shows up during mood episodes, the diagnosis is a mood disorder with psychotic features. If mood symptoms are present but don’t meet full episode criteria or don’t last long enough, the diagnosis is schizophrenia.
Schizoaffective disorder has historically been one of the least reliable diagnoses in psychiatry, with poor consistency between clinicians. The DSM-5 attempted to improve this by making it a longitudinal diagnosis, meaning clinicians must evaluate the entire course of illness rather than just what’s happening at a single point in time.
Cognitive Differences Between the Two
One of the clearest distinctions between schizophrenia and affective psychoses is cognitive functioning. People with schizophrenia tend to show broader and deeper cognitive impairment, particularly in IQ, processing speed tasks like symbol coding, and verbal learning. The gap between schizophrenia and psychotic mood disorders is most pronounced in verbal learning and current IQ, with roughly moderate effect sizes separating the groups.
Perhaps more telling is what happens before diagnosis. People who go on to develop schizophrenia often show measurable cognitive decline from childhood through late adolescence, years before psychotic symptoms appear. This pattern of premorbid intellectual impairment is fairly specific to schizophrenia. Studies comparing premorbid IQ in people who later develop schizophrenia versus bipolar disorder consistently find the impairment only in the schizophrenia group.
Different Treatments Reflect Different Biology
The medications used for each condition also reflect the categorical distinction. Schizophrenia treatment centers on reducing the activity of dopamine, the brain chemical most directly linked to psychotic symptoms. Most antipsychotics work by blocking dopamine receptors. A newer medication approved in 2024 takes a completely different approach, stimulating a type of acetylcholine receptor to reduce dopamine release upstream, but the end goal is the same: tamp down excess dopamine signaling.
Affective disorders, by contrast, are primarily treated with mood stabilizers and antidepressants that target different chemical systems. There is some crossover: certain antipsychotics are also effective for bipolar disorder, and one dopamine-targeting medication is the only drug in its class approved as a standalone treatment for bipolar depression. But the core pharmacological strategies for the two categories remain distinct, reinforcing that different underlying brain circuits are driving the primary symptoms in each condition.
A Spectrum, Not a Sharp Line
The honest answer is that schizophrenia is definitively not classified as an affective disorder, but the boundary between the two is less absolute than the diagnostic manuals suggest. Seventy percent genetic overlap is enormous. Symptoms bleed across categories. Some patients shift diagnoses over the course of their lives. The current classification system treats them as fundamentally different conditions, and that framework remains clinically useful for guiding treatment. But the biology increasingly points to a spectrum rather than two entirely separate diseases, with schizoaffective disorder occupying the middle ground that Kraepelin’s original dichotomy couldn’t quite account for.